原薬・製剤の規格:分析手法の開発とバリデーション(第3版)<br>Specification of Drug Substances and Products : Development and Validation of Analytical Methods (3RD)

個数:
電子版価格
¥44,552
  • 電子版あり

原薬・製剤の規格:分析手法の開発とバリデーション(第3版)
Specification of Drug Substances and Products : Development and Validation of Analytical Methods (3RD)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 908 p.
  • 言語 ENG
  • 商品コード 9780443134661
  • DDC分類 615.19

Full Description

Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Third Edition contains chapters discussing the unique requirements for the universal critical quality attributes, as well as the specific tests required to characterize and control different types of products, ranging in complexity from small molecules in immediate release oral dosage forms to complex products such as drug-antibody conjugates and mRNA-based products. This substantially expanded revision of the second edition will serve as practical comprehensive reference for scientists, managers, educators, and consultants involved in the development and regulation of pharmaceutical products.

Contents

Section I Introduction
1. Introduction
Section II Regulatory considerations and statistical approaches
2. Principles for setting specifications and shelf lives
3. Stability studies: General regulatory considerations and regional differences
4. Kinetics and mechanisms of drug degradation
5. Analytical procedure life cycle management
6. Process analytical technology
7. Pharmacopeial methods and tests
8. Development of United States Pharmacopeia-National Formulary (USPeNF) Monographs and General Chapters
9. The distinctiveness of the British Pharmacopeia and its relationship to other Pharmacopeia
10. Specifications and analytical procedures in registration applications
11. Specifications and analytical proceduresin clinical trial applications
Section III Critical quality attributes
12. Description and identification Ernest Parente
13. Assay and impurities: Specifications of new chemical entities ("small molecules")
14. Assay and impurities: Method development as part of analytical life-cycle management
15. Assay and impurities: Method validation
16. Mutagenic impurities
17. Residual solvents
18. Elemental and inorganic impurities
19. Extractables and leachables
20. Microbiology methods
21. Solid-state methods: An overview
22. Solid-state characterization e Method development and validation
23. Chiral methods
24. Water determination
Section IV Dosage forms and product types
25. Orally administered dosage forms
26. Drug release: Topical products
27. Transdermal products
28. Inhalation products
29. Ophthalmic products
30. General analytical considerations for parenteral products
31. Specification of biotechnology products including cell and gene therapy
32. Biotechnology products: Validation of analytical methods
33. Biosimilars
34. Antibody-drug conjugates
35. Oligonucleotides
36. Specifications for vaccines
37. Nanoparticle suspension dosage forms by nanomilling
38. Development of connected drug delivery systems
Section V Biological fluids
39. Bioanalysis of biological matrix samples using liquid chromatography-tandem mass spectrometry detection
40. Bioanalysis of oligonuceotides

最近チェックした商品